99 related articles for article (PubMed ID: 3552212)
1. 2,6-Diaminopurinedeoxyriboside as a prodrug of deoxyguanosine in L1210 cells.
Weckbecker G; Cory JG
Cancer Res; 1987 May; 47(9):2218-23. PubMed ID: 3552212
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activation of 2,6-diaminopurine and 2,6-diaminopurine-2'-deoxyriboside to antitumor agents.
Weckbecker G; Cory JG
Adv Enzyme Regul; 1989; 28():125-44. PubMed ID: 2624171
[TBL] [Abstract][Full Text] [Related]
3. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
4. Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells.
Weckbecker G; Weckbecker A; Lien EJ; Cory JG
Cancer Res; 1987 Feb; 47(4):975-8. PubMed ID: 2433036
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
Cass CE; Tan TH; Selner M
Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Sato A; Montgomery JA; Cory JG
Cancer Res; 1984 Aug; 44(8):3286-90. PubMed ID: 6611198
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of deoxycytidine rescue of thymidine toxicity in human T-leukemic lymphocytes.
Fox RM; Tripp EH; Tattersall MH
Cancer Res; 1980 May; 40(5):1718-21. PubMed ID: 6989492
[TBL] [Abstract][Full Text] [Related]
9. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
Kang GJ; Kimball AP
Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
[TBL] [Abstract][Full Text] [Related]
10. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
11. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
Cory AH; Samano V; Robins MJ; Cory JG
Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
[TBL] [Abstract][Full Text] [Related]
12. Potentiation by 2'-deoxycoformycin of the inhibitory effect by 3'-deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells in vitro.
Glazer RI; Lott TJ; Peale AL
Cancer Res; 1978 Aug; 38(8):2233-8. PubMed ID: 307428
[TBL] [Abstract][Full Text] [Related]
13. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of herpes simplex virus replication by purine deoxyribonucleosides.
North TW
Cancer Res; 1984 Apr; 44(4):1415-9. PubMed ID: 6322976
[TBL] [Abstract][Full Text] [Related]
15. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
16. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
Weckbecker G; Weckbecker A; Lien EJ; Cory JG
J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
[TBL] [Abstract][Full Text] [Related]
17. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877
[TBL] [Abstract][Full Text] [Related]
18. [Modulation of the antitumor activity of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a by O(6)-methyl-2'-deoxyguanosine--a new inhibitor of O(6)-alkylguanine-DNA-alkyltransferase].
Dederer LIu; Sokolova IS; Bakhmedova AA; Miniker TD; Mel'nik SIa; Gorbacheva LB
Biokhimiia; 1995 Sep; 60(9):1521-9. PubMed ID: 8562657
[TBL] [Abstract][Full Text] [Related]
19. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
Cass CE; Selner M; Phillips JR
Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
White EL; Shaddix SC; Brockman RW; Bennett LL
Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
